Janux Therapeutics, Inc., was incorporated in Delaware on June 27, 2017. The Company is an innovative biopharmaceutical company developing next-generation therapies based on the Company's proprietary Tumor-Activated T-Cell Enginator (TRACTr) platform technology to better treat cancer patients. The company's initial focus is to develop a new class of T-cell adapters (TCE), and the company's main product candidates are designed for clinically validated drug targets. 

Janux Therapeutics's 15-minute chart has recently exhibited a narrowing of Bollinger Bands, coupled with a KDJ Death Cross on September 11, 2026 at 15:15. This suggests that the magnitude of fluctuations in the stock price has been decreasing, and the momentum has shifted towards the downside, indicating a potential for further decreases in the stock price.Janux Therapeutics (JANX) has recently shown signs of bearish momentum on its 15-minute chart, with the Bollinger Bands narrowing and a KDJ Death Cross forming at 15:15 on September 11, 2026. These technical indicators suggest a reduction in price volatility and a shift in momentum toward the downside, potentially signaling <a href="https://www.google.com/goto?url=CAESqgEB6zswFT77vmNuFakRz-tDbNlUSOSpD6pdh4tphDBVmwT8Ke1FkmRYpUnuixfy-miQeJ_n4C3hNAKghqfVgd8Ar0nxM6SLN4cXInKWlh3pephcinM7Wav8skEd_xiKD7he3gVN9Aor_Q7fZ4TILOPgVlQlm3nAccaSSpb49f0VarFXnsb8ZCGDt0QiqRDeYDTnuTPyRx-KEvoTS45D7pUUksYzcBrbMp6SWA">further declines in the stock price</a>.The narrowing of the Bollinger Bands indicates that the stock is entering a period of consolidation, with price fluctuations becoming less pronounced. This pattern is often interpreted as a precursor to a breakout or breakdown, depending on the direction of the subsequent price movement. In this case, the KDJ Death Cross—a bearish signal—adds weight to the <a href="https://www.google.com/goto?url=CAESqgEB6zswFT77vmNuFakRz-tDbNlUSOSpD6pdh4tphDBVmwT8Ke1FkmRYpUnuixfy-miQeJ_n4C3hNAKghqfVgd8Ar0nxM6SLN4cXInKWlh3pephcinM7Wav8skEd_xiKD7he3gVN9Aor_Q7fZ4TILOPgVlQlm3nAccaSSpb49f0VarFXnsb8ZCGDt0QiqRDeYDTnuTPyRx-KEvoTS45D7pUUksYzcBrbMp6SWA">possibility of a downward trend</a>.Janux Therapeutics has faced mixed signals in recent months. While the company has demonstrated promising clinical data in the treatment of metastatic castration-resistant prostate cancer (mCRPC), the stock has also been affected by operational challenges, including a <a href="https://www.google.com/goto?url=CAESqgEB6zswFT77vmNuFakRz-tDbNlUSOSpD6pdh4tphDBVmwT8Ke1FkmRYpUnuixfy-miQeJ_n4C3hNAKghqfVgd8Ar0nxM6SLN4cXInKWlh3pephcinM7Wav8skEd_xiKD7he3gVN9Aor_Q7fZ4TILOPgVlQlm3nAccaSSpb49f0VarFXnsb8ZCGDt0QiqRDeYDTnuTPyRx-KEvoTS45D7pUUksYzcBrbMp6SWA">recent earnings miss and</a> the departure of key leadership. These factors may have contributed to the bearish technical signals observed in the short-term chart.Investors are advised to monitor both technical and fundamental developments closely. While the technical indicators suggest a period of lower volatility and potential downward pressure, the company’s clinical progress and market opportunity could provide <a href="https://www.google.com/goto?url=CAESqgEB6zswFT77vmNuFakRz-tDbNlUSOSpD6pdh4tphDBVmwT8Ke1FkmRYpUnuixfy-miQeJ_n4C3hNAKghqfVgd8Ar0nxM6SLN4cXInKWlh3pephcinM7Wav8skEd_xiKD7he3gVN9Aor_Q7fZ4TILOPgVlQlm3nAccaSSpb49f0VarFXnsb8ZCGDt0QiqRDeYDTnuTPyRx-KEvoTS45D7pUUksYzcBrbMp6SWA">support for a recovery</a> in the longer term.

JanuxTherapeutics

Janux Therapeutics' 15min chart triggers Bollinger Bands Narrowing, KDJ Death Cross signal.

Janux Therapeutics' 15-minute chart recently exhibited an RSI Oversold condition and a KDJ Golden Cross at 09/11/2026 12:00. This suggests that the stock price has experienced a rapid decline, potentially falling below its fundamental support level. However, the momentum of the stock price is now shifting towards an upward trend, indicating potential for further increases.On September 11, 2026, Janux Therapeutics, Inc. (JANX) exhibited a notable technical development on its 15-minute chart, with the Relative Strength Index (RSI) entering an oversold condition and a KDJ Golden Cross occurring at 12:00 PM. These signals suggest that the stock price has experienced a sharp decline, potentially dipping below its fundamental support level. However, the momentum appears to be shifting, with <a href="https://www.google.com/goto?url=CAESeAHrOzAVzVXFWFMNkYSzbBlrny_UYQtU-8HaPhUJeX3S-UMRfxjFFpJyecRpGW2GfQLaeFSSLKMCHuzpGT14lUhEVq_MZH4RaE_MnMyJhqxILkx9nAqeNOFeIHvLEs79Tn2ZJiQJsriHI9yDjPiY7tTVZ_fBGQg00Q">early signs of an upward trend</a> emerging.The stock closed at $17.68, with mixed signals from key technical indicators. Shorter-term moving averages, such as the 8-day and 20-day SMAs, suggest a sell signal, while longer-term indicators like the 50-day and 200-day SMAs indicate a buy signal. The MACD (12, 26) stands at 0.79, supporting a buy recommendation, while the <a href="https://www.google.com/goto?url=CAESeAHrOzAVzVXFWFMNkYSzbBlrny_UYQtU-8HaPhUJeX3S-UMRfxjFFpJyecRpGW2GfQLaeFSSLKMCHuzpGT14lUhEVq_MZH4RaE_MnMyJhqxILkx9nAqeNOFeIHvLEs79Tn2ZJiQJsriHI9yDjPiY7tTVZ_fBGQg00Q">RSI of 47.78 suggests</a> the stock is oversold.The Bollinger Bands (25) show a range of (16.47 - 19.21), and the <a href="https://www.google.com/goto?url=CAESeAHrOzAVzVXFWFMNkYSzbBlrny_UYQtU-8HaPhUJeX3S-UMRfxjFFpJyecRpGW2GfQLaeFSSLKMCHuzpGT14lUhEVq_MZH4RaE_MnMyJhqxILkx9nAqeNOFeIHvLEs79Tn2ZJiQJsriHI9yDjPiY7tTVZ_fBGQg00Q">100-day Bollinger Bands range</a> is (13.94 - 17.24), both indicating potential for upward movement. While the stock’s technical indicators suggest a possible reversal, investors should remain cautious and consider broader market conditions and fundamental factors before making investment decisions.

Janux Therapeutics's 15min chart shows RSI Oversold and KDJ Golden Cross.

Janux Therapeutics' 15-minute chart has recently triggered an oversold RSI reading and a golden cross on the KDJ indicator, which occurred at 16:00 on September 10, 2026. This suggests that the stock price has fallen rapidly and is currently below its fundamental support level. Furthermore, the momentum of the stock price is shifting towards an upward trajectory, indicating potential for further increases.On September 10, 2026, at 16:00, Janux Therapeutics, Inc. (NASDAQ: JANX) experienced a notable technical development on its 15-minute chart. The stock triggered an oversold reading on the Relative Strength Index (RSI), a momentum oscillator that measures the speed and change of price movements. An oversold condition typically indicates that a stock may be undervalued and could be <a href="https://www.google.com/goto?url=CAESbAHrOzAVS7ULPKSF6q2przYnUXPC7aj-cN0SOxnmHYH6xyo0Rvgc5qwBbkhXIorldKUuZa-Elh9E7bXhLusi7it3ejhWz7Is3BruX80U2iEJ4tBI4OQmhVUvvH7HJfUj00M5zF2f1NB2SLeCQw">due for a price rebound</a>.Simultaneously, the KDJ indicator, a stochastic oscillator used to identify overbought and oversold conditions, formed a golden cross. A golden cross occurs when the 50-period moving average crosses above the 200-period moving average, <a href="https://www.google.com/goto?url=CAESbgHrOzAV_sZOp101aYMtlYzKNvsqJo68AaUi4wMjJIXQjUYhGfZxih2mzjryiOMdiqO1pDdor3kcmskofoRtA4zER3jOimBTm-dl1AdhGvKxY2XJyTFZANdB5wupcNfPpnk5YczXc6qMa8rlVNu0">signaling a potential reversal</a> from a downtrend to an uptrend. In this case, the crossover on the KDJ indicator suggests that the stock’s momentum is shifting in favor of buyers.The stock price has fallen rapidly in recent sessions, currently trading below its fundamental support level. This rapid decline has created a scenario where the price may be poised for a corrective upward movement. While the stock remains under pressure in the broader context—evidenced by its 8-day and 20-day simple and exponential moving averages indicating sell signals—<a href="https://www.google.com/goto?url=CAESeAHrOzAVpTavKGPB-ojyLa_EpNtYjoGeYxr7fWmqsvSsuX0ICC1FCMxvXxJwC1v11uBjWim20he3sJlnyY00MGhwHs5xI-MILmRrpWX-Ndn4CayC-QsXDWj3p7RNK7pXNV6NcV9zkzVwapaeROFG_9v_WuwXV5UQRg">shorter-term indicators suggest a potential reversal</a>.Investors and traders should monitor the stock closely for follow-through buying and whether the price can hold above key moving averages. As with all technical signals, confirmation through price action and volume is essential before making investment decisions.

Janux Therapeutics' 15-minute chart has recently exhibited a notable trend reversal, as evidenced by the RSI Oversold and KDJ Golden Cross indicators on September 10, 2026, at 15:00. This suggests that the stock price has fallen precipitously and is trading below its fundamental support levels, resulting in a shift in momentum towards the upside. Consequently, there is a potential for further price appreciation in the coming days.On September 10, 2026, Janux Therapeutics (JANX) displayed a significant trend reversal on its 15-minute chart, marked by the <a href="https://www.google.com/goto?url=CAESdQHrOzAVADXBbkj-8qTMCLx4xiSl-6axoDPR1x0GI1PIQr56D5QcODO2N-QkBFoFU9dL3-uXutmKfdU0zZ1_FHkUm0RcqnBJ0tiQ-JF_WNlOdeWFOhWftfQaJ8frHbZ3jyAobuNHx7fMX-N7g681HqQ3xm6fVw">KDJ Golden Cross indicators</a>. These signals suggest that the stock has experienced a sharp decline, <a href="https://www.google.com/goto?url=CAESdQHrOzAVADXBbkj-8qTMCLx4xiSl-6axoDPR1x0GI1PIQr56D5QcODO2N-QkBFoFU9dL3-uXutmKfdU0zZ1_FHkUm0RcqnBJ0tiQ-JF_WNlOdeWFOhWftfQaJ8frHbZ3jyAobuNHx7fMX-N7g681HqQ3xm6fVw">below its fundamental support</a> level of $16.00. The shift in momentum indicates a potential reversal in the stock’s trajectory, with signs of upward movement gaining traction.Technical indicators such as the RSI and moving averages have historically supported a positive outlook for JANX. The RSI curve has shown a <a href="https://www.google.com/goto?url=CAESdQHrOzAVADXBbkj-8qTMCLx4xiSl-6axoDPR1x0GI1PIQr56D5QcODO2N-QkBFoFU9dL3-uXutmKfdU0zZ1_FHkUm0RcqnBJ0tiQ-JF_WNlOdeWFOhWftfQaJ8frHbZ3jyAobuNHx7fMX-N7g681HqQ3xm6fVw">rising trend, reinforcing bullish</a> momentum. Additionally, the stock’s <a href="https://www.google.com/goto?url=CAESdQHrOzAVADXBbkj-8qTMCLx4xiSl-6axoDPR1x0GI1PIQr56D5QcODO2N-QkBFoFU9dL3-uXutmKfdU0zZ1_FHkUm0RcqnBJ0tiQ-JF_WNlOdeWFOhWftfQaJ8frHbZ3jyAobuNHx7fMX-N7g681HqQ3xm6fVw">positive volume balance</a>—characterized by high volume on up days and low volume on down days—further supports the strength of the upward move.While the stock remains within its defined support and resistance range, a <a href="https://www.google.com/goto?url=CAESdQHrOzAVADXBbkj-8qTMCLx4xiSl-6axoDPR1x0GI1PIQr56D5QcODO2N-QkBFoFU9dL3-uXutmKfdU0zZ1_FHkUm0RcqnBJ0tiQ-JF_WNlOdeWFOhWftfQaJ8frHbZ3jyAobuNHx7fMX-N7g681HqQ3xm6fVw">breakout above $22.70</a> could signal a stronger continuation of the upward trend. Investors are advised to monitor key levels and volume patterns for confirmation of the reversal’s sustainability.

The 15-minute chart for Janux Therapeutics has triggered both the RSI Oversold and KDJ Golden Cross indicators on September 9, 2026, at 15:15. This suggests that the stock price has dropped precipitously and has fallen below its fundamental support level. Furthermore, the momentum of the stock price appears to be shifting towards an upward trend, indicating that there may be potential for further increases in the future.On September 9, 2026, at 15:15, the 15-minute chart for Janux Therapeutics (JANX) triggered both the RSI Oversold and KDJ Golden Cross indicators, signaling a potential reversal in the stock’s price trajectory. The RSI Oversold condition suggests that the stock has experienced a sharp decline, falling below its fundamental support level, while the KDJ Golden Cross indicates a shift in momentum toward a potential upward trend. These technical signals may suggest that the stock could experience a rebound in the near term.From a broader perspective, Janux Therapeutics has outperformed the S&amp;P 500 across multiple time horizons. Year-to-date, the stock has returned 40.51%, compared to 11.71% for the S&amp;P 500. Over the past three years, it has <a href="https://www.google.com/goto?url=CAESXQHrOzAVLdazzicojajNObtfrqOUguzEKdpJDhNOH6SNNxBxIk2yWlKVEzLIYO-PSUtSrcmtf9wqrbzWW2YLV3gBzOC0lkp0qsHd97yyCcqq7SoSKYJArfmiqXWMfw">delivered a 90.38% return</a>, versus 71.55% for the benchmark index. Analysts remain cautiously optimistic, with <a href="https://www.google.com/goto?url=CAESbAHrOzAVQ5F6P7f_K3PPn-ndMmQjHKuc6WX7i2MqP5E1aJXLakZf92VLF6RXzzQimhsOPoMq3OPiaY6ubKozmohk5Njdv6sJAc8IwbmS0j7deIOCpR5kVquTJ_SjaIKe6z1clx5x6BBWP-9l5Q">a consensus Buy rating</a> based on the company’s strong pipeline and innovative technology platforms. Investors are advised to monitor upcoming clinical data updates and broader market conditions for further guidance.

JANX News